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We investigated the tear cytokine proﬁles in patients who underwent stem cell transplantation (SCT) and
attempted to evaluate whether tear cytokines are associated with the presence of systemic chronic
graft-versus-host disease (GVHD), regardless of ocular GVHD status. We also tested tear cytokines as bio-
markers for chronic ocular GVHD severity. Forty-four patients who underwent SCT were enrolled and their
diagnosis of chronic GVHD was conﬁrmed. Ocular surface parameters and tear cytokine proﬁles were eval-
uated and the correlations between concentrations of cytokines and ocular surface parameters or several
chronic ocular GVHD severity scales were evaluated. Tear interleukin (IL)-2, IL-10, IL-17a, interferon (IFN)-g,
IL-6, and tumor necrosis factor (TNF)-awere elevated in patients with chronic systemic GVHD compared with
patients without chronic systemic GVHD. Receiver-operating characteristic curve analysis revealed that area
under the curve (AUC) values for tear IL-10 (AUC ¼ .795), IL-17a (AUC ¼ .821), IL-6 (AUC ¼ .912), and TNF-a
(AUC ¼ .910) were signiﬁcantly correlated with the presence of chronic GVHD (all P < .001). Tear IL-10, IL-6,
and TNF-a showed a stronger correlation with ocular surface parameters than other cytokines and these
cytokines also correlated with several chronic ocular GVHD severity scales (all P < .05). Our data suggest the
tear cytokines are useful biomarkers for the diagnosis of chronic GVHD after SCT and chronic ocular GVHD
severity.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION and B cells, stimulate aberrant production of cytokines,
Chronic graft-versus-host disease (GVHD) is the main
cause of morbidity and mortality after allogeneic hemato-
poietic stem cell transplantation (SCT) [1]. More than 50% of
patients who receive allogeneic bone marrow transplants
develop chronic GVHD [2]. Furthermore, in peripheral blood
stem cell recipients, the risk of chronic GVHD is known to be
higher than that observed in bone marrow transplantation
patients [3]. Aberrant immune system recovery is thought to
play an important role in GVHD pathophysiology [4,5]. Im-
mune cells, including alloreactive and autoreactive T cellsedgments on page 2084.
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ty for Blood and Marrow Transplantation.which play important roles in chronic GVHD [6-8]. Several
biological markers, including these cytokines, have been re-
ported for the prediction and diagnosis of chronic GVHD, and
the markers were mainly identiﬁed in blood samples [9].
Recently, tear analysis has been demonstrated to be a
useful biomarker for various ocular surface diseases [10-12],
including dry eye disease, meibomian gland disease, and
allergies, as well as systemic diseases such as diabetes mel-
litus [13], cancer [14], and thyroid-associated disease [15].
These biomarkers also indicate disease progression and
response to treatment [16]. Although tear ﬂuid analysis
needs clinical validation, its beneﬁts lie in its fast, easy, and
noninvasive sampling [11]. A few studies have reported
increased levels of tear cytokines in patients with chronic
ocular GVHD [17,18].
The purpose of the present study was to investigate tear
cytokine proﬁles in patients who underwent SCT and to
J.W. Jung et al. / Biol Blood Marrow Transplant 21 (2015) 2079e20852080determine the ability of tear-derived biomarkers to conﬁrm
the presence of chronic GVHD. Furthermore, we evaluated
tear cytokines as biomarkers for chronic ocular GVHD
severity by assessing the correlation of ocular surface pa-
rameters and several established chronic ocular GVHD
severity scales.
MATERIALS AND METHODS
Patients
This study followed the tenets of the Declaration of Helsinki, and the
prospective study protocol was approved by the Severance Hospital Insti-
tutional Review Board, Seoul, South Korea. Informed consent was obtained
from all patients after explaining to them the purpose and possible conse-
quences of the study.
Forty-four patients were enrolled in this study and they consulted our
ophthalmology clinic after SCT for mainly ocular GVHD screening without
ocular symptoms or ocular complaints. Male or nonpregnant female pa-
tients ages 15 to 60 years who visited the clinic 3 to 12 months after SCT
were included in the study. We excluded patients with histories of ocular
surgery; ocular injury; and ocular diseases such as ocular infection, allergy,
and autoimmune disease, as well as patients with long-term use of topical
ocular medications except artiﬁcial tears. Diagnostic criteria for chronic
GVHD used the National Institute of Health (NIH) consensus criteria [19]
deﬁned as follows: “diagnosis of chronic GVHD requires the presence of at
least 1 diagnostic clinical sign (eg, polikiloderma or esophageal web) or the
presence of at least 1 distinctive manifestation (eg, keratoconjunctivitis
sicca) conﬁrmed by pertinent biopsy or other relevant tests in the same or
another organ” [19,20].
Patients with and without chronic GVHD were compared for de-
mographic and clinical characteristics (Table 1). No signiﬁcant differences
were detected for age and period after SCT (P ¼ .919 and .173, respectively).
Outcome Measures
The primary outcomemeasures of this studywere tear cytokine proﬁles.
These results were compared for patients with andwithout chronic GVHD toTable 1
Demographics of Patients with and without Chronic GVHD after SCT
Characteristic No Chronic
GVHD after
SCT (n ¼ 14)
Chronic GVHD
after SCT
(n ¼ 30)
Age, yr*
Median (range) 36.5 (16-59) 39.0 (15-51)
Mean  SD 36.5  9.9 36.0  12.4
Female, n (%) 6 (42.9%) 11 (36.7%)
Hematologic diagnosis, n (%)
AML 5 (35.7%) 14 (46.7%)
ALL 6 (42.9%) 15 (50.0%)
Non-Hodgkin’s lymphoma 0 (0.0%) 1 (3.3%)
Aplastic anemia 3 (21.4%) 0 (0.0%)
Stem cell source, n (%)
PB 13 (92.9%) 24 (80.0%)
BM 1 (7.1%) 6 (20.0%)
Manifestations of chronic GVHD at time
of tear sampling, n (%)
Gastrointestinal tract 5 (16.7%)
Lung 12 (40.0%)
Liver 13 (43.3%)
Oral cavity 17 (56.7%)
Skin 24 (80.0%)
Eye 27 (90.0%)
Systemic immunosuppressive treatment
at time of tear sampling, n (%)
None 2 (14.3%) 2 (6.7%)
Calcineurin inhibitor 3 (21.4%) 3 (10.0%)
Steroid 6 (42.9%) 17 (56.7%)
Calcineurin inhibitor þ steroid 3 (21.4%) 8 (26.7%)
Period after SCT, monthsy
Median (range) 9.5 (4-12) 9.4 (3-12)
Mean  SD 8.4  3.6 9.9  2.7
AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; PB,
peripheral blood; BM, bone marrow.
* Using Mann-Whitney U test (P value ¼ .919).
y Using Mann-Whitney U test (P value ¼ .173).determine the utility of tear cytokines as biomarkers to diagnose chronic
GVHD regardless of ocular GVHD diagnosis. The secondary outcomes were
correlations between tear cytokines and ocular surface parameters or
several criteria assessing the severity of ocular GVHD to evaluate the value of
tear cytokines as biomarkers for chronic ocular GVHD severity.
All patients underwent slit-lamp examination to measure the ocular
surface staining score, ﬂuorescein tear ﬁlm break-up time (TBUT), and
conjunctival injection grade. The patients underwent Schirmer’s test I, and
the ocular surface disease index (OSDI) questionnaire was completed. Tear
samples were collected and tear cytokine concentrations were measured.
TBUT was measured by applying a single ﬂuorescein strip (Haag-Streit,
Koeniz, Switzerland) to the inferior palpebral conjunctiva after instilling a
drop of normal saline. The mean time for 3 attempts was recorded. After
measuring TBUT, ocular surface stainingwas graded from 0 to 5 based on the
pattern of ﬂuorescein staining noted on slit-lamp biomicroscopy [21].
Conjunctival injection grade was scored as 0, 1, or 2 [20]. Schirmer’s test I
was performed without topical anesthesia by placing a standard paper strip
in the mid-lateral portion of the lower fornix. The amount of wetting was
recorded after 5 minutes, and patients were asked to keep their eyes lightly
closed during the test. Subjective symptoms were graded on a numerical
scale from 0 to 4, according to the validated 12-item OSDI questionnaire.
Total OSDI was calculated using the following formula: OSDI ¼ (sum of
scores for all questions answered  100)/(total number of answered
questions  4), which ranges from 0 to 100 [22]. Classiﬁcation of conjunc-
tivitis in chronic GVHD [23], the NIH eye score [19], and a recently reported
severity scale by the international chronic ocular GVHD consensus group
[20] were used as the criteria for assessing the severity of ocular GVHD to
evaluate the correlation with tear cytokine concentrations (Table 2).
Tear Collection and Multiplex Bead Analysis
To collect tear samples, 30 mL of phosphate-buffered saline was instilled
into the inferior fornix and 20 mL of tear ﬂuid and buffer were collected with
a micropipette at the medial and lateral canthus. To minimize ocular surface
irritation, we collected the mixture of tear ﬂuid and buffer solution as soon
as possible, without the use of anesthetic eye drops. The sample was
transferred into .5-mL Eppendorf tubes (Eppendorf, Fremont, CA) and stored
at 70C until further analysis by immunoassay. Cytokine concentrations
were measured using a multiplex immunobead assay (BDTM Cytometric
Bead Array Human Soluble Protein Flex Set; BD Biosciences, San Jose, CA).
The analyzed cytokines were interleukin (IL)-2, IL-10, IL-17a, IL-4, interferon
(INF)-g, IL-6, and tumor necrosis factor (TNF)-a. The measurements were
performed as previously described [24,25]. Datawere acquired and analyzed
using BD Cytometric Bead Array software, which calculated the cytokine
concentration on the basis of standard curves and a 4-parameter logisticTable 2
Chronic Ocular GVHD Severity Scales
Classiﬁcation of Conjunctivitis in Chronic GVHD [23]
0 None
1 Hyperemia
2 Palpebral conjunctival ﬁbrovascular changes with or without
epithelial sloughing
3 Palpebral conjunctival ﬁbrovascular changes involving 25% to 75% of
total surface area
4 Involvement of>75% of total surface area with or without cicatricial
entropion
NIH-Deﬁned Ocular Scoring in Chronic GVHD [19]
0 No dry eye symptoms
1 Dry eye symptoms not affecting ADL (eye drops 3 per day) or
asymptomatic signs of keratoconjunctivitis sicca
2 Dry eye symptoms partially affecting ADL (eye drops >3 per day or
punctual plugs) without vision impairment
3 Dry eye symptoms signiﬁcantly affecting ADL (special eye wear to
relieve pain) or unable to work because of ocular symptoms or loss
of vision caused by keratoconjunctivitis sicca
Severity Scale in Chronic Ocular GVHD by the International Chronic
Ocular GVHD Consensus Group [20]
Severity
Scores
(Points)
Schirmer’s
Test (mm)
CFS
(Points)
OSDI
(Points)
Conj
(Points)
0 >15 0 <13 None
1 11-15 <2 13-22 Mild/Moderate
2 6-10 2-3 23-32 Severe
3 5 4 33
ADL indicates activities of daily living; CFS, corneal ﬂuorescein staining;
Conj, conjunctival injection.
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system (BD Biosciences). The lower limits of detection were as follows: IL-2,
2.6 pg/mL; IL-10, 4.5 pg/mL; IL-17a, 18.9 pg/mL; IL-4, 4.9 pg/mL; IFN-g, 3.7
pg/mL; IL-6, 2.4 pg/mL; and TNF-a, 3.8 pg/mL. The value 0 was used for
statistical comparison between tear samples with concentrations below the
value of the lowest cytokine concentration (detection limit) in the linear
portion of the standard curve.
Statistical Analysis
The Mann-Whitney U test was used to compare the outcomes between
patients with and without chronic GVHD. The effect of tear cytokine con-
centration on the diagnosis of chronic GVHDwas assessed after adjusting for
age, sex, and the period after SCT by a logistic regression model. Receiver
operating characteristic curves were generated to provide evidence of a
biomarker’s discriminating ability for chronic GVHD diagnosis and to esti-
mate the best level to be used as a cut-off value. Spearman’s rank correlation
coefﬁcient was used to assess correlations between several variables stud-
ied. Statistical analyses were performed using SPSS for Windows (version
20.0; SPSS Inc., Chicago, IL) and MedCalc for Windows, version 14.0 (Med-
Calc Software, Ostend, Belgium). P values less than .05 were considered
signiﬁcant.
RESULTS
Forty-four patients were evaluated for the diagnosis of
chronic GVHD and 30 of themwere diagnosed using the NIH
consensus criteria [19]. Twenty-seven patients (90.0%) had
chronic ocular GVHD and many other organs were involvedFigure 1. Tear cytokine concentrations in patients with chronic graft-versus-host
interleukin (IL)-2, IL-10, IL-17a, IL-4, interferon (IFN)-g, IL-6, and tumor necrosis factor
for each group. *P < .05, **P < .01, ***P < .001 using Mann-Whitney U test.(gastrointestinal tract, 16.7%; lung, 40.0%; liver; 43.3%; oral
cavity, 56.7%; skin, 80.0%) (Table 1).
Figure 1 shows comparisons of tear cytokine concentra-
tions between patients with and without chronic GVHD. All
measured cytokines, except IL-4, were elevated in patients
with chronic GVHD compared with those in patients without
chronic GVHD (IL-2, P¼ .026; IL-10, P¼ .007; IL-17a, P¼ .008;
IL-4,P¼ .158; IFN-g,P¼ .02; IL-6,P< .001; andTNF-a,P<.001).
The diagnostic abilities of tear IL-10, IL-17a, IL-6, and TNF-a
were signiﬁcant and independent in the logistic regression
model after adjusting for age, sex, and time period after SCT
(odds ratio for IL-10,2.499; for IL-17a,1.038; for IL-6,1.036; and
for TNF-a, 1.024) (Table 3). Using receiver operating charac-
teristic curve analyses, these 4 cytokines showed that all the
area under the curve (AUC) valueswere greater than .70: IL-10,
.795; IL-17a, .821; IL-6, .912; and TNF-a, .910 (P < .001 for all).
For chronic GVHDdiagnosis, the cut-off valueswere .82 pg/mL
for IL-10 (sensitivity 56.7%, speciﬁcity 85.7%), 20.26 pg/mL for
IL-17a (sensitivity 66.7%, speciﬁcity 78.6%), 81.08 pg/mL for
IL-6 (sensitivity 76.7%, speciﬁcity 100%), and 81.89 pg/mL
for TNF-a (sensitivity 73.3%, speciﬁcity 100%) (Figure 2).
The ocular surface parameters, including staining scores,
TBUT, conjunctival injection, Schirmer’s test I scores, and
OSDI scores were signiﬁcantly higher in the chronic GVHDdisease (GVHD) and without chronic GVHD. Tear cytokines were tested for
(TNF)-a by multiplex immunobead assay. Horizontal bars indicate mean values
Table 3
Logistic Regression Model for the Diagnostic Abilities of Tear Cytokine
Concentrations for Chronic GVHD Diagnosis after Adjusting for Age, Sex, and
the Period after SCT
Cytokine Odds Ratio 95% CI P Value
IL-2 2.02 .978-4.170 .057
IL-10 2.499 1.007-6.207 .048
IL-17a 1.038 1.007-1.070 .018
IL-4 1.47 .734-2.943 .277
IFN-g 1.397 .892-2.190 .145
IL-6 1.036 1.009-1.065 .010
TNF-a 1.024 1.004-1.044 .018
CI indicates conﬁdence interval.
Signiﬁcant correlations are in bold font.
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all) (Table 4). The correlations between tear cytokines and
ocular surface parameters were assessed in all subjects
(Table 5). In particular, tear IL-10, IL-6, and TNF-a showed
moderate or strong correlation (r ¼ .4 or greater), and they
were more strongly correlated with several ocular surface
parameters than other cytokines.
Figure 3 shows that the severity of chronic ocular GVHD
correlated signiﬁcantly with tear cytokines, especially IL-10,Figure 2. Receiver operating characteristic (ROC) curve of tear cytokine concentration
the curve (AUC)  standard error (SE) ¼ .795  .071; 95% CI (.647 to .902); P < .0
(AUC  SE ¼ .912  .042; 95% CI (.787 to .976); P < .001), and TNF-a (AUC  SE ¼ .9IL-6, and TNF-a. Classiﬁcation of conjunctivitis in chronic
GVHD correlated with IL-10 (r¼ .467, P¼ .003), IL-6 (r¼ .684,
P < .001), and TNF-a (r ¼ .533, P < .001). There were signif-
icant correlations between the NIH eye score and IL-10
(r ¼ .508, P ¼ .001), IL-6 (r ¼ .421, P ¼ .008), and TNF-a
(r ¼ .444, P ¼ .005). The severity scale by international
chronic ocular GVHD consensus group correlated with IL-10
(r ¼ .464, P ¼ .003), IL-6 (r ¼ .598, P < .001), and TNF-a
(r ¼ .570, P < .001).
DISCUSSION
The focus of the present study was to compare the tear
cytokine proﬁles in patients with or without newly diag-
nosed chronic GVHD after SCT. Levels of tear IL-2, IL-10,
IL-17a, IFN-g, IL-6, and TNF-a were elevated in patients with
chronic GVHD compared with patients without chronic
GVHD. A few studies reported increased levels of tear cyto-
kines in patients with chronic ocular GVHD [17,18]. Riemens
et al. [17] demonstrated that tear IL-6 and IFN-g levels were
elevated and correlated with dry eye symptoms. However,
they performed tear sampling by Schirmer’s test strips, and
IL-6 and IFN-gwere detected in 44% and 50% of SCT patients,
respectively; other cytokines were not detected. To the bests for predicting the diagnosis of chronic GVHD. ROC curve of IL-10 (area under
01), IL-17a (AUC  SE ¼ .821  .066; 95% CI (.677 to .920); P < .001), IL-6
10  .044; 95% CI (.784 to .975); P < .001).
Table 4
Ocular Parameters of Patients with and without Chronic GVHD after SCT
Ocular Surface Parameters No Chronic
GVHD after
SCT (n ¼ 14)
Chronic GVHD
after SCT
(n ¼ 30)
P Value*
Ocular surface staining, 0-5
Median (range) 0 1 (0-3) <.001
Mean  SD 0 1.3  0.7
TBUT, sec
Median (range) 8 (0-10) 0 (0-8) <.001
Mean  SD 6.7  3.9 1.8  2.7
Conjunctival injection, 0-2
Median (range) 0 (0-1) 1 (0-2) <.001
Mean  SD 0.1  0.3 1.2  0.6
Schirmer I score (mm)
Median (range) 11 (6-23) 2 (0-14) <.001
Mean  SD 11.4  4.9 3.4  4.0
OSDI score
Median (range) 2.08 (0-10.42) 33.96 (0-68.75) <.001
Mean  SD 3.2  3.6 17.6  7.7
SD indicates standard deviation.
* Using Mann-Whitney U test.
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cytokines proﬁle in patients with chronic GVHD, regardless
of presence of ocular GVHD.
Fewstudies [26,27]have also suggested thatbiomarkers for
chronic GVHD could differ with regard to the time of chronic
GVHDonset from SCT; therefore,we limited the time after SCT
to 3 to 12months and tried to adjust the period for analysis. As
a result, tear cytokines, especially IL-10, IL-17a, IL-6, and TNF-a,
signiﬁcantly correlated with the presence of chronic GVHD
and their diagnostic abilities for chronic GVHD diagnosis were
signiﬁcant. Several studies have evaluated the biological
markers of chronic GVHD diagnosis using mainly blood
samples and not tears, and the ﬁndings of these studies sup-
port increased proinﬂammatory cytokines, including TNF-a,
IL-6, IL-1b, IL-8, the soluble alpha chain of the IL-2 receptor
(sIL-2R), and IL-1Ra [9,28,29]. Because previous studies could
not classify chronic GVHD as either pure Th1 or Th2 disease
[9,30], we used the human Th1/Th2/Th17 cytokine kit in the
present study. We observed increased levels of all tear cyto-
kines except IL-4, which indicates Th2 cell differentiation. A
lack of Th2 shift has been known to activate B cells by
up-regulating the expression of B celleactivating factor in
GVHD [9,30]. Although the role of IL-10 in GVHD pathogenesis
remains poorly understood, there are reports showing both
beneﬁcial and adverse effects of this cytokine in GVHD pro-
gression [31,32]. Notwithstanding the unclear role of IL-10 inTable 5
Correlations between Tear Cytokine Levels and Ocular Surface Parameters in Patie
Cytokine Ocular Surface Staining TBUT Sc
IL-2 .123 .303 
P ¼ .455 P ¼ .060 P
IL-10 .327 .268 
P [ .042 P ¼ .099 P
IL-17a .251 L.344 
P ¼ .123 P [ .032 P
IL-4 .011 .303 
P ¼ .948 P ¼ .061 P
IFN-g .130 .312 
P ¼ .429 P ¼ .054 P
IL-6 .630 .289 L
P < .001 P ¼ .074 P
TNF-a .462 L.416 
P [ .003 P [ .008 P
Numbers are Spearman’s correlation coefﬁcients. Signiﬁcant correlations are in bochronic GVHD, increased levels of IL-10 imply its applicability
in the diagnosis of chronic GVHD [9], as seen in our results.
The NIH consensus of chronic GVHD indicates that dry eye
is a distinctive sign of chronic GVHD but insufﬁcient in itself
to establish a diagnosis of chronic GVHD until conﬁrmation
by biopsy or other tests in the same organ or other organ
[19]. However, this requirement can interfere with the early
diagnosis of systemic chronic GVHD. Evidence supporting
the classiﬁcation of dry eye disease as a diagnostic clinical
entity for chronic GVHD has been recently published [20]. In
our study, the results of tear cytokine analysis showed a
signiﬁcant correlation with their scores for chronic GVHD
diagnosis, and thus, the results can be signiﬁcant for possible
diagnosis of chronic GVHD, not limited to the chronic ocular
GVHD diagnosis.
We also investigated the role of tear cytokines as bio-
markers for chronic ocular GVHD severity by showing their
signiﬁcant correlations with ocular surface parameters and
the previously known classiﬁcations of chronic ocular GVHD
severity. Speciﬁcally, tear IL-10, IL-6, and TNF-a showed
stronger correlations with ocular surface parameters than
other cytokines, and these cytokines also correlated with
several chronic ocular GVHD severity scales. Although rela-
tively little information exists on biomarkers for chronic
GVHD severity using other samples [9], TNF-a, IL-6, and IL-1b
levels have been suggested as candidate biomarkers [9,29].
Tear IL-6 and TNF-a have been known to correlate with
symptoms and signs of ocular surface disease such as
dysfunctional tear syndrome, Sjögren syndrome, and mei-
bomian gland dysfunction [10,17,25,33,34]. Increased levels
of proinﬂammatory cytokines, such as IL-6, can cause the
differentiation of naive CD4þ cells to Th17 T cells, which have
been identiﬁed as key effector cells in autoimmune processes
[35]. Th17 cells, with the characteristic production of IL-17,
can mediate the development of GVHD in mice [36]. In
multiple mouse strains, blocking IL-6 signaling dramatically
attenuates GVHD and Th17 responses [37,38]. However, Th17
responses may not be the only prerequisite for the devel-
opment of GVHD [39]. Moreover, in humans, the role of IL-6
in ocular GVHD might not only be to promote Th17 but also
to promote the differentiation of B cells and the induction of
antibody production [40]. Our study showed that the in-
crease in proinﬂammatory cytokines IL-6 and TNF-a and the
increase in IL-17 coincided very well and were correlated
with each other.
There are several criteria for assessing the severity of
chronic ocular GVHD. We used the NIH eye score, which is ants Who Underwent SCT
hirmer I Score Conjunctival Injection OSDI Scores
.205 .133 .340
¼ .212 P ¼ .421 P [ .034
.237 .492 .542
¼ .147 P [ .001 P < .001
.211 .252 .238
¼ .196 P ¼ .122 P ¼ .145
.131 .088 .271
¼ .428 P ¼ .596 P ¼ .095
.241 .171 .336
¼ .139 P ¼ .298 P [ .036
.446 .586 .488
[ .004 P < .001 P [ .002
.296 .518 .603
¼ .067 P [ .001 P < .001
ld font.
Figure 3. Scattergram showing the correlations between classiﬁcation of conjunctivitis in chronic GVHD (A), the NIH eye scores (B), and the severity score by the
International Chronic Ocular GVHD Consensus Group (C) and tear cytokines, IL-10, IL-6, and TNF-a. Spearman’s correlation coefﬁcients were used.
J.W. Jung et al. / Biol Blood Marrow Transplant 21 (2015) 2079e20852084clinical scoring system proposed as NIH consensus criteria in
2005 as part of a global assessment of chronic GVHD severity
[19] and classiﬁcation of conjunctivitis in chronic GVHD [23].
Although it is still controversial, conjunctival involvement in
chronic GVHD indicates a sign of severe chronic GVHD and
decreased survival of patients [41]. In this present study, tear
IL-10, IL-6, and TNF-a level signiﬁcantly correlated with both
severity criteria. Moreover, tear cytokine concentrations
showed a signiﬁcant correlation with the severity score of
the most current system of chronic GVHD diagnosis [20],
which was reported by the International Chronic Ocular
GVHD Consensus Group. Therefore, the measurement of
these tear cytokines is expected to be useful in assessing
chronic ocular GVHD severity.
This study had some limitations. Although we analyzed a
relatively large sample size in comparison to previous studies
and considered time differences, this study was a cross-
sectional observation case series with inherent selection bias
because patients were referred to an eye clinic. Thus, larger
scale prospective design studies are necessary to conﬁrm the
role of tear cytokine biomarkers for chronic GVHD. Moreover,
the analysis of tear cytokines warrants additional clinical
validation and improvement in clinical utility.In conclusion, tear cytokine proﬁles differed signiﬁcantly
according to the presence of newly diagnosed chronic GVHD.
Our study demonstrated suggested certain tear cytokines as
promising new possible diagnostic markers of chronic GVHD
and criteria for chronic ocular GVHD severity. Because tear
sampling is noninvasive and simple, it is expected to be
applicable for the screening and diagnosis of chronic GVHD.ACKNOWLEDGMENTS
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